MONTREAL, Nov. 29, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP.TO) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development today announced the filing of three patent applications for its novel therapeutic, ARDS-003.
Read more at prnewswire.comTetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here